Company GENinCode Plc

Equities

GENI

GB00BL97B504

Medical Equipment, Supplies & Distribution

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

Ratings for GENinCode Plc

EPS Revisions

Annual profits - Rate of surprise

Sector Diagnostic & Testing Substances

Market Closed - London S.E. Other stock markets 11:35:27 2024-05-21 am EDT			5-day change	1st Jan Change
8.25 ^GBX	0.00%		+1.54%	+57.14%

Apr. 04	GENinCode Plc Announces Publication by the American Journal of Preventive Cardiology of A Study on 'Polygenic Risk and Incident Heart Disease in a Large Multiethnic Cohort	CI
Mar. 21	GENinCode says ROCA recommended as ovarian cancer risk test in England	AN

GENinCode Plc is a United Kingdom-based polygenics company focused on the prevention of cardiovascular disease and ovarian cancer. The Company operates business units in the United Kingdom, Europe through GENinCode S.L.U, and in the United States through GENinCode U.S. Inc. Its predictive technology provides patients and physicians with preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict cardiovascular disease. The Company's core products include Cardio inCode - Score and Check - Coronary predictive/risk assessment; Thrombo inCode - Hematology, Recurrent Pregnancy Loss and Oncology, Thrombosis (blood clots) predictive/risk assessment; Lipid inCode - Familial Hypercholesterolemia Diagnosis and risk stratification, and SudD inCode - Hereditary Cardiomiopathies diagnosis, Risk assessment for sudden cardiac events.

Number of employees: 34

GBP in Million	2021	Weight	2022	Weight	Delta
Clinical Genetics Tests 100.0 %	1	100.0 %	1	100.0 %	+23.92%

GBP in Million	2021	Weight	2022	Weight	Delta
Spain 84.4 %	1	86.7 %	1	84.4 %	+20.58%
Italy 9.2 %	0	8.2 %	0	9.2 %	+38.95%
United Kingdom 2.5 %	-	-	0	2.5 %	-
France 2.5 %	0	2.8 %	0	2.5 %	+12.50%
Chile 0.4 %	0	0.7 %	0	0.4 %	-25.00%
Mexico 0.4 %	-	-	0	0.4 %	-
Peru 0.4 %	0	0.5 %	0	0.4 %	0.00%
Sweden 0.1 %	0	0.3 %	0	0.1 %	-75.00%

Managers	Title	Age	Since
Matthew Walls FOU	Founder	60	18-09-05
Jordi Gilberte FOU	Founder	49	18-09-05
Paul Foulger DFI	Director of Finance/CFO	55	20-10-31

Members of the board	Title	Age	Since
Paul Foulger DFI	Director of Finance/CFO	55	20-10-31
Matthew Walls FOU	Founder	60	18-09-05
William Rhodes CHM	Chairman	70	20-12-31
Felix Frueh BRD	Director/Board Member	56	22-04-05
Huon Gray BRD	Director/Board Member	-	22-01-20
Jordi Gilberte FOU	Founder	49	18-09-05
Sergio Rigau BRD	Director/Board Member	63	20-04-30

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	176,964,426	101,155,198 ( 57.16 %)	0	57.16 %

Name	Equities	%	Valuation
Octopus Investments Ltd. 17.66 %	31,255,672	17.66 %	3 M p
Santi 1990 SL 11.41 %	20,190,182	11.41 %	2 M p
Jordi Puig 8.252 %	14,602,500	8.252 %	1 M p
Jordi Gilberte 8.184 %	14,482,500	8.184 %	1 M p
Matthew Walls 6.647 %	11,762,500	6.647 %	1 M p
Downing LLP 6.010 %	10,635,672	6.010 %	965 506 p
MATTIOLI WOODS PLC 6.010 %	10,635,672	6.010 %	965 506 p
Foresight Group LLP 5.785 %	10,236,864	5.785 %	929 303 p
Maven Capital Partners UK LLP 5.746 %	10,168,758	5.746 %	923 120 p
Maitland Asset Management (Pty) Ltd. 4.784 %	8,465,154	4.784 %	768 467 p

GENinCode Plc

1, St. Peters Square

M2 3DE, Manchester

http://www.genincode.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Estimates Revisions

Company calendar

Healthcare

Healthcare Services

Healthcare Equipment & Supplies

Medical Equipment, Supplies & Distribution

Diagnostic & Testing Substances

	1st Jan change	Capi.
GENINCODE PLC	+57.14%	18.56M
BIOMÉRIEUX	-6.26%	12.1B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-3.93%	8.16B
DIASORIN S.P.A.	+7.10%	5.78B
LANTHEUS HOLDINGS, INC.	+30.16%	5.59B
AUTOBIO DIAGNOSTICS CO., LTD.	-7.47%	4.23B
10X GENOMICS, INC.	-57.20%	2.87B
ANDON HEALTH CO., LTD.	+12.56%	2.71B
VITROLIFE AB	-4.67%	2.35B
MYRIAD GENETICS, INC.	+27.38%	2.21B

Diagnostic & Testing Substances